In addition, elevated NAP1L1 level was shown as potential diagnostic and unfavorable prognostic biomarkers for some tumors and stimulated tumor progression and doxorubicin chemotherapy resistance in tumors including colorectal cancer [10, 11], renal cancer [12], liver cancer [13–15], glioblastoma [16] and pancreatic neuroendocrine neoplasm [17]. This evidence concerns the gene NAP1L1 and renal carcinoma.